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Introduction
Classical radiobiology has focused primarily on intracellular 
effects from radiation therapy (RT) and DNA damage 
mediated cell death (1). However, more contemporary 
data suggest that the cytotoxic effects of RT are intimately 
related and dependent on the immune system. In 2009 
researchers from University of Chicago demonstrated the 
importance of CD8+ T cells for the therapeutic effects from 
ablative RT (2). This finding was replicated by a group from 
Japan (3), and demonstrated that CD8+ T cell depletion 
could induce radioresistance.
Immune mediated effects of RT begin with the 
expression of damage-associated molecular patterns 
(DAMPs) (4). These factors include the release of high 
mobility group box 1 (HMGB1) nuclear protein by 
dying tumor cells, which interact with Toll-like receptor 
4 (TLR4) on dendritic cells (DCs) (5). HMGB1 may be 
expressed even when cell viability is unaltered with RT (6), 
and results in dose-dependent immunostimulation in the 
local microenvironment. In a rodent melanoma model, 
DCs exhibited increased major histocompatibility complex 
(MHC) expression within 48 hours of RT exposure (2). 
This permits the presentation of normally suppressed tumor 
associated antigens that are required for immune mediated 
cell kill.
RT has stimulatory, but also inhibitory effects on the 
immune system. High dose RT may also increase PD-
L1 expression and terminate the inflammatory response 
through negative feedback. As a result, anti-cytotoxic 
T-lymphocyte associated antigen 4 (CTLA-4) and anti-
programmed death-1 (PD-1) inhibitors may work 
synergistically to improve outcomes after RT (7,8). In 
a murine hepatocellular carcinoma (HCC) model, RT 
was found to upregulate PD-L1 expression through an 
IFN-γ/STAT3 mediated signaling pathway. As a result, the 
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combination of anti-PD-L1 treatment with RT induced 
tumor growth delay and improved survival in this cancer 
model (9). 
Radiotherapy has been shown to generate abscopal effects 
resulting in the response of metastatic tumor deposits not 
directly treated with RT. Excitement regarding the clinical 
utility of this phenomena was fueled by a melanoma study 
examining the use of RT following ipilimumab. Roughly 
half of all patients in this study experienced an abscopal 
response with a corresponding increase in survival from 
8.3 to 22.4 months (10). Although the mechanism of these 
effects is not clear, an increase in tumor infiltrating CD8+ T 
cells is commonly observed (9,11).
Given the intimate relationship between RT and 
immunogenic cell  death, as well  as the advent of 
immunotherapy drugs designed to uncloak tumor cells 
to immune surveillance, researchers are now exploring 
the utility of focal RT in combination with systemic 
immunotherapy. Although this combination is being tested 
in virtually all tumor subtypes, this review will be focused 
on data relevant to gastrointestinal malignancies. 
Esophageal and gastric cancers
RT plays an important role in both the curative and 
palliative management of esophageal and gastric cancers, 
either alone or as a part of multimodality treatment. In 
patients eligible for surgery, the addition of preoperative 
chemoradiotherapy (CRT) improves overall survival (OS), 
progression-free survival (PFS), and negative margin rates 
compared to esophagectomy alone (12). Definitive CRT is 
potentially curative for non-operable esophageal cancers 
and is associated with 5-year OS of 34–59% (13-16). 
Unlike for esophageal cancers the role of CRT versus 
chemotherapy alone for operable gastric tumors remains 
controversial. A systemic meta-analysis published in 
2009 demonstrated that the addition preoperative 
or postoperative RT was associated with improved 
OS compared to surgery alone (17). The addition of 
postoperative CRT in resectable gastric cancer has been 
shown to improve OS and PFS with acceptable toxicity (18). 
However,  there is  also randomized evidence that 
perioperative chemotherapy improves OS compared 
to surgery alone and is another standard of care option 
for locally advanced gastric cancers as an alternative to 
postoperative CRT (19,20). Multiple trials are currently 
evaluating chemotherapy alone versus CRT including 
T O P G E A R  ( N C T 0 1 9 2 4 8 1 9 )  a n d  C R I T I C S - I I 
(NCT02931890) in the preoperative setting and ARTIST-
II (NCT01761461) in the postoperative setting (21-23). 
Definitive CRT for localized gastric cancer is reserved for 
inoperable patients (24). RT alone is typically utilized in the 
palliative setting and is effective for the majority of patients 
to alleviate dysphagia, bleeding, and pain (25). 
The long-term outcomes remain poor for esophageal and 
gastric cancers with conventional therapies. Preclinical and 
emerging clinical data demonstrate that immunotherapy 
may significantly benefit at least a subset of these patients, 
especially when combined with RT. Additionally, 27% 
of gastric and 19% of esophageal carcinomas were found 
to express high levels of DNA damage response gene 
alterations. These mutations are associated with resistance 
to chemotherapy and RT, but may sensitize tumors to 
immunotherapy due to the increased mutational burden (26). 
Programmed death-ligand 1 (PD-L1) is expressed in 45% 
and 38% of esophageal and gastric cancers, respectively 
(27-30). The prognostic significance of PD-L1 expression 
remains to be defined. The expression of another less well 
studied checkpoint molecule, IDO-1, has been correlated 
with poor OS for both AC and SCC of the esophagus (31). 
Co-expression on IDO-1 and PD-L1 in pre-treatment 
biopsies of 158 Chinese patients was found to be predictive 
for poor pathologic complete response (pCR) and increased 
risk of recurrence in esophageal SCC (32). 
Chimeric antigen receptor (CAR)-T cells engineered 
to target HER2 or the folate receptor have shown some 
preclinical efficacy in vitro and in animal models of 
gastric cancers (33,34). Preclinical models are currently 
investigating the potential of combining CAR-T cells with 
RT or chemotherapy in order to increase efficacy (35,36). 
Adoptive cellular immunotherapy with cytokine induced 
killer cells/dendritic cells (CIKC/DC) has also shown 
efficacy in esophageal and gastric cancer and can be further 
enhanced by RT (37,38). Priming dendritic cells of elderly 
patients with esophageal cancers prior to reintroducing 
them after RT has been shown to lead to improved response 
rates compared to RT alone (39). 
In esophageal cancer, exposure to RT leads to increase 
of PD-L1 expression in vitro and in vivo (27,40). Although 
there are data that pretreatment PD-L1 may be considered 
a negative prognostic factor, increased expression after CRT 
may be associated with improved OS (41). Additionally, 
CRT has also been shown to increase the overall 
immunogenicity of esophageal tumors even in the absence 
of changes in PD-L1 expression (42). Other modulators of 
the immune system are also in preclinical investigation, such 
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as thymosin alpha 1, a synthetic amino acid peptide, which 
upregulates MHC1. Emerging data suggest that improved 
LC may result when thymosin alpha 1 is combined with 
stereotactic body radiation therapy (SBRT) in metastatic 
heavily pre-treated esophageal cancers (43). The utility of 
RT in combination with immunotherapy is further being 
investigated in metastatic esophageal cancer in an ongoing 
clinical trial (NCT02642809). We are awaiting results from 
several ongoing studies investigating the benefit from adding 
immunotherapy to definitive CRT in inoperable esophageal 
cancers (NCT03377400, NCT03437200) or adjuvant 
chemotherapy following standard of care treatment (44). 
HCC
HCC is the most common form of primary liver cancer 
comprising 75–85% of cases. Most frequently seen in 
countries with high hepatitis B virus or hepatitis C virus 
infection rates it is the 6th most common cause of cancer 
worldwide and the 4th leading cause of cancer death (45). 
Surgical resection and liver transplantation are the first 
line therapies for HCC; however, the majority of patients do 
not undergo surgery due to comorbid conditions including 
advanced liver cirrhosis, metastatic disease, or limited 
availability of donor livers (46). Locoregional therapies 
such as RT, chemoembolization, radioembolization, or 
radiofrequency ablation are alternative treatments for 
patients who are not candidates for surgery or who are 
awaiting a donor liver. Due to high rates of background 
liver cirrhosis, recurrence of HCC is common even after 
locoregional therapies (47). 
Systemic therapies are often prescribed to reduce the 
risk of locoregional and distant disease recurrence, but their 
efficacy has largely been suboptimal. Traditional cytotoxic 
chemotherapies have limited effectiveness in HCC and are 
often not administrable due to underlying liver cirrhosis. 
Sorafenib and lenvatinib are tyrosine kinase inhibitors (TKI) 
that have been approved as first line systemic therapies for 
patients with unresectable HCC, while regorafenib and 
cabozantinib have been approved in the second line (47). 
These agents improve survival on the order of three months 
or less compared to placebo (47). Novel therapies are 
greatly needed to improve outcomes for HCC patients.
The HCC tumor microenvironment although rich with 
lymphocytes is predominantly immunosuppressive, thus 
enabling cancer cells to grow with little immune regulation. 
Multiple immunotherapy strategies are being studied to 
counteract the immunosuppressive tumor microenvironment 
or stimulate immune-mediated cell kill (48). In 2017, 
the PD-1 checkpoint inhibitor nivolumab was the first 
immunotherapy agent approved for the treatment of HCC 
based on an objective overall response rate (ORR) of 
14.3% in the CHECKMATE-040 phase 1/2 clinical trial. 
Ninety-one percent of responders had responses lasting 
6 months or longer and 55% had responses lasting 
12 months or longer. Twenty-five percent of patients 
had a grade 3–5 treatment-related adverse event (49). In 
the following year the PD-1 inhibitor pembrolizumab 
was approved in patients that had been previously 
treated with sorafenib based on an ORR of 17% in the 
KEYNOTE-224 phase 2 clinical trial (50). The subsequent 
phase III randomized trial, KEYNOTE-240, comparing 
pembrolizumab to placebo did not meet its co-primary 
endpoints of OS and PFS (51), but the CHECKMATE-459 
randomized trial comparing nivolumab to sorafenib as first-
line therapy has yet to be reported. 
The use of other checkpoint inhibitors, either alone 
or in combination with PD-1 inhibitors, may unlock the 
potential of checkpoint blockade. The CTLA-4 inhibitor 
tremelimumab was evaluated in a phase 1 trial for patients 
with HCC and showed a disease control rate of 76.4% 
and time to progression of 6.5 months (52). Due to the 
low response rates typically seen with CTLA-4 inhibitors 
alone it is being combined with PD-1 inhibitors with the 
hope of improving efficacy. The phase 3 randomized trial 
HIMALAYA is comparing the combination of temelimumab 
and the PD-L1 inhibitor, durvalumab, to sorafenib 
(NCT03298451). We await the results of multiple ongoing 
randomized clinical trials testing PD-1, PDL-1 or CTLA-
4 inhibitors for HCC (NCT03794440, NCT03298451, 
NCT02702401,  NCT02576509,  NCT03755739, 
NCT03062358,  NCT03713593,  NCT03847428, 
NCT03764293, NCT03434379). Other checkpoint 
inhibitors such as, T-cell immunoglobulin and mucin 
domain containing-3 (TIM-3), transforming growth factor-β 
(TGF-β), and lymphocyte activation gene 3 (LAG-3) 
are also being tested in ongoing clinical trials either alone 
or in combination with PD-1 blockade (NCT03680508, 
NCT02947165, NCT03538028).
Adoptive cell transfer is the process of passively 
administering autologous lymphocytes following ex vivo 
cultivation in order to augment the immune response 
to a cancer. Three subtypes of lymphocytes are being 
studied for HCC: natural killer (NK) cells, cytokine-
induced killer (CIK) cells, and chimeric antigen receptor 
T (CAR-T) cells (53). Donor NK cells stimulated by 
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interleukin-2 (IL-2) were shown to have no adverse events 
when administered to patients with cirrhosis and HCC 
undergoing liver transplantation (54). Ongoing clinical 
trials are investigating the administration of NK cells versus 
sorafenib (NCT03563170) and combining NK cell transfer 
with irreversible electroporation (NCT03008343). CIK 
cells are created by incubating monocytes with cytokines 
and a monoclonal antibody against the T cell marker 
CD3. CIK cells have shown cytotoxic effects against HCC 
in vitro and in vivo (55). A randomized phase 3 trial of CIK 
cell administration after RFA, ethanol injection or resection 
showed a 14-month improvement in recurrence-free 
survival (56). After gaining FDA approval for the treatment 
of lymphoma, CAR-T cell therapy is also being studied for 
the treatment of various solid tumors, including HCC. HCC 
commonly expresses number of tumor-associated antigens 
that make for potential targets for CAR-T cell therapy 
including, GPC-3, EpCAM and AFP (57,58). The only 
published trial to date for CAR-T cell therapy for HCC was 
an abstract of a phase I trial which demonstrated no dose-
limiting toxicity and only one grade 3 adverse event (59). 
There are multiple ongoing clinical trials exploring the 
use of CAR-T cell therapy for HCC (NCT03198546, 
NCT03130712,  NCT02715362,  NCT03013712, 
NCT02723942).
Intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (IHC) is the second 
most common primary liver cancer with an incidence 
of 5,000 new cases in the United States each year (45). 
Frequently diagnosed at advanced stages, only about 20% 
of patients with newly diagnosed IHC are candidates for 
surgery. Unlike HCC, IHC is responsive to cytotoxic 
chemotherapies. The combination of gemcitabine and 
cisplatin are first-line agents for advanced IHC, and 
are commonly prescribed along with RT, TACE and 
radioembolization. Unfortunately, outcomes remain poor 
with long term survival infrequent due to high rates of 
recurrent disease. 
To date, no immunotherapy agents have yet been 
approved for the treatment of IHC. Cancers with mismatch 
repair (MMR) deficiencies have been shown to have a high 
mutational load and respond frequently to checkpoint 
inhibitors. Pembrolizumab was approved for the treatment 
of solid tumors with MMR deficiencies, regardless of 
histology (60). MMR deficiency has been reported in 5–10% 
of IHCs (61), and MMR-deficient IHC have been shown to 
have an overall response rate to pembrolizumab of 53% (62). 
Microsatellite stable (MSS) IHCs have also shown 
responsiveness to checkpoint inhibitors. In a phase 2 trial 
testing nivolumab as a second-line agent, 55% of patients 
achieved stable disease or a partial response with a median 
PFS of 3.5 months (63).
Based on these encouraging early results, numerous 
clinical trials are underway testing immunotherapy 
strategies for the treatment of IHC. Checkpoint inhibitors, 
sometimes combined with other systemic agents, are being 
tested in multiple phase I or II trials (NCT03201458, 
NCT04003636,  NCT03473574,  NCT03250273, 
NCT02834013,  NCT02628067,  NCT03095781, 
NCT02393248, NCT02821754, NCT03257761), adoptive 
cell transfer investing CIK and CAR-T cells alone or 
in combination with checkpoint inhibitors or RFA are 
also being tested in phase I-III trials (NCT02482454, 
NCT03633773, NCT02757391). A phase 2 cancer vaccine 
trial is also underway (NCT03042182). 
Due to the potential synergistic effects of RT and 
immunotherapy for the treatment of a variety of solid 
tumors seen in multiple preclinical studies, RT and 
immunotherapy combinations are being tested in 
multiple clinical trials for both HCC and IHC. The 
safety of SBRT followed by the checkpoint inhibitors 
nivolumab or ipilimumab is being tested in a phase 1 trial 
(NCT03203304). Nivolumab is also being combined with 
yttrium-90 radioembolization prior to hepatectomy in a 
phase I trial (NCT03812562). Sequential TACE followed 
by SBRT and immunotherapy is being tested in a phase 
2 clinical trial to downstage HCC prior to hepatectomy 
(NCT03817736). Finally, a phase 2 study is investing the 
combination of gemcitabine, cisplatin, anti-PD-1 antibody 
and SBRT for the treatment of IHC (NCT03898895).
Pancreatic cancer
Pancreatic cancer ranks among the deadliest malignancies 
with over 45,000 individuals succumbing to this disease 
each year in the United States (64). Half of all patients 
present with metastatic disease with under a 5% probability 
of surviving 5 years (65,66). For those eligible for surgery, 
historical results have shown steady increases in 3-year 
survival from 14% in the 1970s, 21% in the 1980s, to 
36% in the 1990s (67). Much of this improvement may be 
credited to refinements in surgical techniques which cut 
perioperative mortality from 30% in the 1970s to 1% by the 
2000s (68). Nevertheless, 5-year survival with surgery alone 
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is estimated at only 18% (68). With advances in adjuvant 
therapy, median survival has climbed to almost 5 years after 
resection for select patients (69).
Unfortunately, only 33% of unresectable pancreatic 
cancers are converted to resection with neoadjuvant 
strategies involving RT and chemotherapy (70). Not 
surprisingly, the response to preoperative treatment 
correlates highly with survival. In a contemporary cohort 
of patients who underwent neoadjuvant CRT followed by 
surgery, limited treatment response was associated with 
a median survival of 26 months in comparison to over 
60 months for those achieving pCR (P<0.001) (71). More 
importantly, only 10% of patients achieved pCR (71), 
emphasizing the need for therapeutic strategies to enhance 
pCR rates.
Given the poor results with conventional therapies for 
pancreatic cancer the utility of immunotherapy has garnered 
significant attention. Initial interest was supported by 
observations demonstrating a positive correlation between 
the presence of CD4+ and CD8+ T cells in pancreatic tumors 
and survival (P<0.01) (72). However, pancreatic cells create an 
immunosuppressive microenvironment through the secretion 
of a variety of factors including TGF-β, IL-10, Gal-1, 
and IDO (73,74). Many pancreatic tumors also express 
PD-L1 and have a poorer prognosis due to reduced tumor 
infiltrating lymphocytes, particularly CD8+ T cells (75). 
The tumor microenvironment is also characterized by the 
presence of regulatory CD4+ T cells, mast cells, tumor-
associated macrophages, and myeloid-derived suppressor 
cells that stymie immune surveillance (76). 
As a result of the poorly immunogenic microenvironment 
in pancreatic cancers, trials involving immunotherapy have 
thus far been disappointing. In contrast to many other solid 
tumors, anti-PD-L1 treatment has shown no response 
in pancreatic cancers (77). Anti-CTLA-4 monotherapy 
was also tested in a phase II study, and again showed no 
response (78). These initial results with monotherapies 
prompted examination of combination strategies. A recently 
completed phase II study compared durvalumab (a PD-L1 
inhibitor) alone versus durvalumab with tremilimumab, but 
only showed a modest gain in the response rate from 0% to 
3% with multi-agent treatment (79).
The suboptimal results from immune checkpoint 
inhibition have increased interest in strategies that may 
convert pancreatic cancers to more immunogenic tumors. 
One approach is through vaccination to induce the 
development of T cells with enhanced targeting capability. 
In 2014 researchers from Johns Hopkins reported 
results from a trial examining an irradiated, granulocyte-
macrophage colony-stimulating factor (GM-CSF—
secreting, allogeneic vaccine (GVAX) given as a single agent 
or in combination with low-dose cyclophosphamide (80). 
Two weeks after vaccine administration tumors were 
resected with specimens demonstrating the formation 
of intratumoral tertiary lymphoid aggregates in 33 of 
39 patients with corresponding improvements in T cell 
trafficking and survival. GVAX has also been tested in 
combination with ipilimumab and found to improve median 
survival from 3.6 to 5.7 months compared to ipilimumab 
alone (81). However, when examined against standard 
chemotherapy, GVAX-based immunotherapy did not 
improve survival (82). Further research into both live and 
peptide-based vaccines remains ongoing.
Recently, researchers from the Medical College of 
Georgia noted that PD-L1 expression could be modified 
through a novel, epigenetic pathway (83). They first noted 
that human mixed lineage leukemia protein-1 (MLL1) 
and PD-L1 were highly expressed in many pancreatic cell 
lines. Then they discovered that MLL1 could bind to the 
H3K4me3 promoter of the CD274 gene, and catalyze the 
promoter to induce expression of PD-L1 from the CD274 
gene. By inhibiting MLL1 they were able to improve 
anti-PD-L1 and anti-PD-1 based immunotherapy (83). 
This novel approach will likely move to clinical trials and 
stimulate additional epigenetic investigations.
Some researchers are examining RT to prime the 
response to immunotherapy after clinical benefits were 
observed with abscopal responses in melanoma (84). 
Preclinical data provide evidence that combining RT and 
immunotherapy maybe a prudent strategy for pancreas 
cancer. Yasmin-Karim et al. showed that combining RT and 
anti-CD40 had a more profound effect on tumor regression 
than either alone in a pancreatic cancer mouse model (85). 
Ongoing trials are evaluating checkpoint inhibitors with 
RT. One single arm phase 2 trial (NCT03490760) in 
metastatic pancreas cancer patients is exploring whether 8 
Gy ×3 delivered sequentially to two different lesions with 
concurrent durvalumab in the second-line improves PFS 
compared to historical control; the intent of irradiating 
multiple lesions is to increase the probability of having 
a more robust anti-tumor response through a RT 
“revaccination” effect given that RT may function like an 
in situ tumor vaccine. 
The ability to predict which patients develop an 
abscopal response is lacking. This is in part due to the 
complex relationship between RT and the immune system. 
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Although RT can induce anti-tumor effects through antigen 
presentation and improved lymphocyte accessibility to 
tumor (86), it may also induce opposing changings such as 
the upregulation of PD-L1 expression (7,87). At least with 
low dose radiation, preclinical data suggests that changes 
are largely favorable and enhance anti-tumor immunity (88).
An additional strategy that warrants further investigation 
is hyperthermia. In preclinical studies hyperthermia 
released heat shock proteins and chemokines that activated 
the immune response (89). Furthermore, hyperthermia 
enhances chemotherapy delivery in pancreatic cancer 
models by inducing tumor stromal changes that may 
also improve access for immune cells (90,91). RT and 
hyperthermia are also complimentary with tumor cells 
sensitive to one or the other at different points in their cell 
cycle. As a result, hyperthermia may be particularly valuable 
in a trimodality approach with RT and immunotherapy (90).
At this time there are over a dozen ongoing clinical 
trials examining various combinations of RT, immunotherapy 
and chemotherapy for pancreatic cancer. Future investigations 
should also incorporate strategies to improve the tumor 
microenvironment with hyperthermia as well as epigenetic 
interventions to sensitize cancer cells to cytotoxic therapies. The 
heterogeneous nature of pancreatic cancers will likely demand 
personalized combinations for each patient and continual 
modification of such strategies throughout their disease course.
Colorectal cancer (CRC)
Immunotherapy for CRC was first explored in the 1980s 
after preclinical models demonstrated the efficacy of 
autologous tumor cell vaccines with an adjuvant [Bacillus 
Calmette-Guérin (BCG)] against injected tumor cells by 
promoting the host’s defense against tumor-specific and 
tumor-associated antigens. The injection of BCG with 
tumor cells was able to promote systemic immunity and halt 
tumor growth (92). 
These results were subsequently evaluated in the 
adjuvant setting in several phase 3 randomized clinical trials 
comparing surgical resection only versus surgical resection 
followed by vaccination. In one study that enrolled 98 
patients beginning in 1981 with stage II-III CRC the 
primary endpoints of OS and disease-free survival (DFS) for 
all patients were not statistically different (HR for OS 1.75, 
P=0.68, HR for DFS 1.58, P=0.147); however, on subset 
analyses, there was found to be a benefit to vaccination in 
patients with colon cancer (HR for OS 2.83, P=0.02; HR 
for DFS 2.67, P=0.39) (93). Another phase 3 trial, E5283, 
examined 412 patients with stage II-III colon cancer and 
demonstrated no differences in OS or DFS (94). In the 
8701 study that evaluated 254 patients with stage II-III 
colon cancer, patients demonstrated a 44% risk reduction 
for recurrence favoring patients that received vaccination 
(P=0.023). Upon subgroup analyses, the impact was only 
seen in patients with stage 2 disease and resulted in a 61% 
risk reduction (95). A meta-analysis was performed including 
the above trials that suggested a benefit to OS and DFS (96). 
Currently, a phase 3 trial is underway further examining the 
role of vaccination in the adjuvant setting for stage 2 colon 
cancer patients. While vaccines have yet to alter routine 
clinical practice, trials are underway to better identify a subset 
of patients who may benefit from vaccination.
Immune checkpoint inhibitors are under active 
investigation for CRC and have demonstrated significant 
efficacy in selected patient population. Initial results with 
PD-1 blockade demonstrated an overall poor response 
amongst all CRC patients; however, a subset of patients with 
mismatch repair (MMR)-deficient tumors, corresponding 
to high levels of microsatellite instability (MSI-H), 
demonstrated greater response. This was hypothesized to 
be due to the high burden of somatic mutations that could 
be more easily recognized by the host immune system. 
The KEYNOTE-016 trial evaluated 41 patients with 
treatment refractory metastatic disease who were treated 
with pembrolizumab across 3 cohorts including MSI-H 
CRC (n=11), mismatch repair-proficient CRC (n=21), and 
MSI-H non-colorectal tumors (n=9). Objective response 
rates (ORRs) were 40%, 0% and 71%, respectively across 
the three cohorts. Median PFS and OS were not reached in 
the MSI-H cohort compared to 2.2 months and 5.0 months, 
respectively, for the mismatch repair-proficient cohort (HR 
for PFS 0.1, P<0.001; HR for OS 0.22, P=0.05) (97). 
These results have led to both the KEYNOTE-164 
trial examining response to pembrolizumab in patients 
with pretreated metastatic MSI-H CRC and the phase 3 
randomized KEYNOTE-177 comparing pembrolizumab 
to investigator choice chemotherapy. Interim results from 
the KEYNOTE-164 trial including 63 patients at a median 
12 months follow up demonstrated an ORR of 32% with 
median PFS of 4.1 months (98,99). 
Combination immune checkpoint inhibition is another 
treatment strategy currently under investigation. The phase 
2 CHECKMATE-142 trial investigated nivolumab with or 
without the addition of ipilimumab for treatment of patients 
with previously treated metastatic MSI-H or MSS CRC. 
Among the MSI-H cohort, ORR was 31.1% for patients 
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treated with nivolumab alone (n=74) and 55% for those 
receiving combination nivolumab and ipilimumab (n=119). 
12-month PFS and OS were 50% and 73%, respectively, in 
the nivolumab alone cohort and 71% and 85%, respectively, 
in the combination therapy cohort. Treatment response was 
observed in patients independent of tumor or immune-cell 
PD-L1 expression, clinical history of Lynch syndrome, or 
BRAF and KRAS mutation status (100,101). 
Further results from the CHECKMATE-142 trial 
regarding patients with MSS disease are forthcoming; 
however, results from numerous trials have failed to show 
significant responses with response rates for MSS patients 
treated with nivolumab or nivolumab and ipilimumab of 
10% or 0%, respectively. Thus, other strategies are under 
investigation to identify other potential immunotherapies. 
A cohort of 23 patients with metastatic CRC were treated 
with a combination of atezolizumab, an anti-PD-L1, 
and cobimetinib, a MEK-inhibitor. MEK inhibition in 
preclinical models have demonstrated increased anti-
PD-L1 activity through increased CD8+ T-cell tumor 
infiltration and MHC-1 upregulation. The ORR was 17% 
with 4 partial responders, 3 of which were MSS (102). A 
phase 2 trial combining ipilimumab and nivolumab with 
RT in metastatic MSS CRC is currently under investigation 
and has enrolled 40 patients. RT induces cellular damage 
within the tumor which may increase responsiveness to 
immunotherapy. Of the 24 patients who received RT, the 
ORR was 12.5% and median duration of disease control 
was 77 days (103). Other combination strategies including 
anti-VEGF or chemotherapy are also under investigation.
Anal cancer
Anal SCC is highly associated with high-risk subtypes of the 
human papilloma virus (HPV). In addition to its oncogenic 
properties, HPV proteins E6 and E7 promotes tumor 
infiltration by lymphocytes and can trigger an anticancer 
host immune response, increasing interest in investigation 
of the role of immunotherapies in the disease (104). 
Recent studies have been published investigating 
the safety and efficacy of PD-1 checkpoint inhibitors in 
treatment refractory anal cancer. KEYNOTE-028 was 
a phase IB multicohort trial assessing pembrolizumab in 
patients with treatment refractory, PD-L1 positive solid 
tumors. Twenty-four patients with anal SCC were enrolled 
and 88% of patients were pretreated. The ORR was 17% 
and an additional 42% of patients had stable disease with a 
median duration of 3.6 months. Median PFS and OS were 
3.0 months and 9.3 months, respectively (105). Similarly, the 
NCI9673 phase 2 study investigated the safety and efficacy 
of nivolumab in 37 patients with treatment refractory 
metastatic anal cancer. 86% of patients had been pretreated 
with a platinum-based chemotherapy and the ORR was 
24% with 7 partial responses and 2 complete responses. 
Median PFS and OS were 4.1 months and 11.5 months, 
respectively with 48% of patients alive at 1 year (106). Both 
regimens were well tolerated without unexpected adverse 
events. Additionally, nivolumab with or without concurrent 
ipilimumab, an anti-CTLA-4 antibody, is currently 
under investigation in patients with treatment refractory 
metastatic anal squamous cell carcinoma (NCT02314169) 
and pembrolizumab alone is currently being evaluated in 
patients with progressive advanced solid tumors including 
anal squamous cell carcinoma after prior treatment failure 
(NCT02628067). 
Integrating immunotherapy with standard combined 
modality therapy including radiation and chemotherapy is 
an area actively under investigation to evaluate the safety 
and potential synergistic effects of treatment. There is a 
current trial investigating the role of nivolumab following 
completion of standard concurrent chemoradiotherapy 
for high risk stage II-IIIB anal squamous cell carcinoma 
(NCT03233711). In addition, there was a recent trial 
evaluating the role of Listeria-based immunotherapy 
given concurrently with mitomycin and cisplatin-based 
chemoradiation. Ten patients with localized anal squamous 
cell carcinoma were enrolled and 9 patients completed 
concurrent treatment. All 9 patients had a complete clinical 
response and 8 patients were free from progression at a 
median follow up of 42 months (107). 
Conclusions
Immunotherapy is changing the treatment paradigm for 
many cancers, and there is increasing evidence that patients 
with gastrointestinal cancers may benefit. Combining 
immunotherapy and RT may be an effective strategy to 
increase the overall anti-tumor immune response for 
gastrointestinal cancer patients, although further evaluation 
is needed in order to better understand predictors of 
response, mechanisms of treatment resistance, and 
biomarkers of toxicity. 
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